DXCM - DexCom, Inc.
212.09 -1.69 (-0.79%)
After hours: 4:11PM EST
| Previous close | 208.37 |
| Open | 209.21 |
| Bid | 210.00 x 900 |
| Ask | 214.64 x 800 |
| Day's range | 208.82 - 214.40 |
| 52-week range | 105.05 - 214.40 |
| Volume | 1,422,524 |
| Avg. volume | 931,167 |
| Market cap | 19.567B |
| Beta (3Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.90 |
| Earnings date | 6 Nov 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 206.31 |
- Zacks
BD's Onclarity HPV PMA Submission to Boost Women's Health
Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.
- Zacks
San Gorgonio Hospital Picks Allscripts Sunrise Community Care
Allscripts' (MDRX) Sunrise Community Care is an Azure-hosted platform offering clinical, financial and ambulatory content.
- Zacks
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
- Zacks
NextGen's Medfusion Buyout to Improve Patient Experience
NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.
- Zacks
5 Relative Price Strength Stocks to Buy for Optimum Returns
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
- Zacks
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Is (DXCM) Outperforming Other Medical Stocks This Year?
- Zacks
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
- Zacks
What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
- Zacks
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
- Simply Wall St.
Is DexCom (NASDAQ:DXCM) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks
DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval
FDA approval for DexCom's (DXCM) G6 Pro boosts the company's broad product spectrum.
- Zacks
Stocks & ETF to Invest in Healthcare Robotics and Innovation
HTEC is poised to benefit from rapid advances in health-care technology
- Zacks
CGM Devices Gain Steam, Set New Trend in Diabetes Management
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
- Zacks
IoMT Becomes the Buzzword in New Age MedTech Investing
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
- Simply Wall St.
Is DexCom, Inc. (NASDAQ:DXCM) Expensive For A Reason? A Look At Its Intrinsic Value
Today we will run through one way of estimating the intrinsic value of DexCom, Inc. (NASDAQ:DXCM) by estimating the...
- Zacks
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
- Motley Fool
Is Dexcom a Buy?
This medical device stock is on a roll. But can its sizzling momentum continue?
- Zacks
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
DexCom (DXCM) has various favorable factors to maintain the current high.
- Motley Fool
Forget the Inverted Yield Curve, These 3 Stocks Just Hit All-Time Highs
The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.
- Motley Fool
Why Insulet's Shares Are Rocketing 20.8% Higher Today
The insulin pump maker's second-quarter financial results are sparking optimism.
- Motley Fool
5 Top Medical Device Stocks to Buy Now
These medical device stocks appear to have what it takes to be long-term winners.
- Zacks
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
